Nuclear Medicine & Molecular Imaging Clinical Trials

  • Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

    This phase II trial is studying the side effects of and how well alisertib works in treatingyoung patients with relapsed or refractory solid tumors or leukemia. Alisertib may stop thegrowth of cancer cells by blocking some of the enzymes needed for cell growth.

    Investigator

    Not accepting patients at this time View Details

  • A Single-Arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors

    This early phase, multicenter, open-label, single-arm study will evaluate the safety,tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of MPDL3280A inpediatric and young adult patients with solid tumors for which prior treatment was proven tobe ineffective.

    Not accepting patients at this time View Details

  • Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer

    The study will be conducted as an open label, single-dose, explorative study with patientswith histologically proven cancer and, preferably, tumor positive lesions in previouslyperformed nuclear medicine imaging examinations.

    The investigational drug will be given as a single administration in a dose of

    Investigators

    Not accepting patients at this time View Details